STAAR Surgical Company · NASDAQ:STAA
STAAR Surgical — Investor Presentation (February 2022)
27 slides from STAAR Surgical's investor presentation, February 2022
Slide 1: STAAR Surgical Investor Presentation
Envision a Life Without Hesitation STAAR Surgical Investor Presentation NASDAQ: STAA | February 2022
Slide 2: Forward Looking Statements
Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such
Slide 3: Who Is STAAR Surgical?
Who Is STAAR Surgical? 01 Proprietary Implantable Collamer® lens (ICL) technology for refractive vision correction 02 Executing against a rapidly expanding global TAM of millions of eyes Primary positioning, collaborative business model 03 and clinical validation are driving industry-leading growth
Slide 4: What is Refractive Vision Correction?
What is Refractive Vision Correction? Surgical procedures designed to correct refractive error (Blurred Vision*) Refractive Refractive Error Surgery Types** Lens-Based Myopia e.g., EVO ICL Presbyopia Laser-Cornea Based Astigmatism Hyperopia We believe the future of refractive vision correction is le
Slide 5: Refractive Error is a Global Epidemic
Refractive Error is a Global Epidemic Myopia • More near work Distance Vision • Less time outdoors • Cell Phones, Screen Time, Gaming, Education, Studying • Astigmatism accompanies myopia Half of the global in ~ 25% of cases* population is 6000 60% expected to have 5000 50% myopia by 2050** 4000 40%
Slide 6: Myopia - The Existing Market is Millions of Eyes
Myopia - The Existing Market is Millions of Eyes 740K 1.1M 4.2M Annual Global Refractive Procedures* 210K 300K 960K Mostly laser and cornea-based Opportunity 910K correction today Low-to-Mid single digits industry growth* STAAR’s ICL growing at 30%+ 6M frequent replacement contact lens wearers drop
Slide 7: STAAR's TAM is Tens of Millions of Eyes
STAAR’s TAM is Tens of Millions of Eyes Global Prevalence STAAR Adjustments to Global Prevalence Epidemiological Data 1.9B 1.7B STAAR’s TAM* Myopes Presbyopes Distribution of Uncorrected Refractive Error Myopia Presbyopia Distance Vision Willingness to Undergo Refractive Near Vision 70M (Nearsighted
Slide 8: STAAR's ICL Technology
An Evolution in Visual Freedom STAAR’S ICL TECHNOLOGY 08
Slide 9: ICLs are Designed to Correct Refractive Error
ICLs are Designed to Correct Refractive Error An ICL (Implantable Collamer® Lens) is a single-piece foldable phakic intraocular lens (IOL) made of STAAR’s proprietary Collamer material and implanted into the posterior chamber EVO ICL™ Family of Lenses Visian ICL™ Family of Lenses Spheric (Myopia) Re
Slide 10: The ICL is Implanted in Front of the Natural Crystalline Lens
The ICL is Implanted in Front of the Natural Crystalline Lens Natural Iris ICL™ Crystalline Lens 10
Slide 11: Happy ICL Patients
Happy ICL Patients 1M+ ICLs Implanted Globally 99.4% of Patients Would Elect STAAR’s EVO Implantable Collamer® Lens Again* * Packer, The Implantable Collamer Lens with a central port: review of the literature, Clinical Ophthalmology, 2018. 11
Slide 12: Premium ICL Patient and Surgeon Advantages
Premium ICL Patient and Surgeon Advantages Quality Excellent No Dry Eye Additive of Vision Night Vision Syndrome Bio- Collamer Quiet in UV Compatible Material the Eye Protection Eco- Removeable Upgradeable No Capital Friendly Equipment Investment 12
Slide 13: ICL Around the World
ICL AROUND THE WORLD 13
Slide 14: China – Continuing Momentum in #1 Global Market
China – Continuing Momentum in #1 Global Market Myopia widespread China: the first large among Chinese market to adopt a population, and model of strategic particularly teenagers* cooperation in 2016 “Hybrid” business model, which has 50+ STAAR employees on the ground in country working in concert w
Slide 15: China – Continuing Momentum in #1 Global Market
China – Continuing Momentum in #1 Global Market Patient roadshows, in-person Tens of thousands of EVO ICL and virtually on social media procedures June, July, August such as WeChat, integral to in China Peak Season demand cycle EVO ICL share of the refractive Greater EVO ICL market grew from approxi
Slide 16: United States – Creating Success in #2 Global Market
United States – Creating Success in #2 Global Market Strategic Imperative Drive U.S. growth, where STAAR currently has < 1% share with an earlier generation lens technology, by successfully introducing, upon approval, our market-transforming EVO family of lenses and executing STAAR’s proven playbook
Slide 17: Europe – Accelerating a Growth Renaissance
Europe – Accelerating a Growth Renaissance Driving growth via Surgeon Support, Strategic Sales & Making sales & marketing investments that include Marketing Investments broadening influencer and social media consumer initiatives Increasing commitment to ICL by surgeons: German refractive society Ent
Slide 18: We're Just Getting Started…
We’re Just Getting Started… ~ 9% ICL share of global market* * Approximate ICL unit share of 2021 global refractive myopia market. 18
Slide 19: STAAR's Track Record of Strong Financial Performance
STAAR’s Track Record of Strong Financial Performance 19
Slide 20: ICL Unit Growth Significantly Exceeds Refractive Industry
ICL Unit Growth Significantly Exceeds Refractive Industry Select Markets, ICL Unit Growth Y/Y Refractive Industry* Global ICL 2021 2020 2019 36% 33% 45% China 16% 48% 60% 17% Japan 59% 65% 11% 34% 4% S. Korea 17% 30% 40% Other APAC Markets 40% 22% 32% Germany 12% 18% (21%) 36% European Distributors
Slide 21: STAAR's Industry Leading Net Sales Growth ~ +25% CAGR
STAAR’s Industry Leading Net Sales Growth ~ +25% CAGR 77% 55% 44% 33% 35% 25% 25% 24% 26% 23% 20% 21% 17% 17% 18% 12% 8% 6% 5% (11%) 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21P $90.6 Million $124.0 Million $150.2 Million $163.5 Million* $230 M
Slide 22: STAAR's Expanding Margins, EPS and Cash
STAAR’s Expanding Margins, EPS and Cash Operating Margin GAAP EPS* Cash from Operations $0.50 7.9% $0.30 $25.8 5.3% $0.11 $0.12 4.1% $ Millions $21.0 $(0.05) $12.8 (4.0%) $2.9 2017 2018 2019 2020 2017 2018 2019 2020 2021P 2017 2018 2019 2020 Cash on Balance Sheet - Quarter-End** $196 $200 $173 $162
Slide 23: STAAR Will Increase Investment in ICL Awareness
STAAR Will Increase Investment in ICL Awareness Impactful Consumer Marketing has driven Increasing ICL Awareness, Doctor Finder Visits and Patients to Surgeons. STAAR intends to make significant incremental investments in awareness building activities in fiscal 2022… China Campaign Global Consumer O
Slide 24: Recent Highlights and Outlook
Recent Highlights and Outlook Reported preliminary sales results STAAR is committed to continuing for fiscal 2021 on January 10, 2022 to push hard to overcome Covid- related challenges Net Sales Growth Doubling the footprint at 40% Y/Y to ~ $230 Million principal manufacturing facility through movem
Slide 25: STAAR's Vision 2020-2022
STAAR’s VISION 2020-2022 We have a Passionate Commitment to Deliver Visual Freedom to Patients for an Active and Fulfilling Life Independent of Contact Lenses and Glasses… 01 Position EVO Implantable Lenses as a Special and Transformational 02 Support the Transformation of the Refractive Surgery Par
Slide 26: STAAR's ESG Commitment
STAAR’s ESG Commitment Published second annual Sustainability Report in 2021 and elevated ESG stewardship to a strategic imperative Several projects completed or underway designed to reduce energy, waste and water, e.g., initial analysis of solar photovoltaic panel initiative indicates STAAR will re
Slide 27: Envision a Life Without Hesitation
Envision a Life Without Hesitation We invite you to visit STAAR’s investor website www.staar.com for clinical papers, examples of global consumer marketing www.discoverevo.com and much more at investors.staar.com
STAAR Surgical Company — Investor Presentation (February 2022) on 6ix